DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the FERMENTA BIOTECH LTD. (FERMENTA) share price today?

FERMENTA BIOTECH LTD. (FERMENTA) is trading at ₹432.65 on the NSE, down 5.83% on the day. Source: DocStoX.

What is the PE ratio of FERMENTA BIOTECH LTD.?

FERMENTA BIOTECH LTD. has a price-to-earnings (PE) ratio of 17.7 in the Healthcare sector.

What is the market capitalisation of FERMENTA BIOTECH LTD.?

FERMENTA BIOTECH LTD. has a market capitalisation of approximately ₹1,280 crore.

FERMENTA BIOTECH LTD.

FERMENTA·NSE·Healthcare

₹432.65▼ -26.80 (-5.83%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹430.20

₹464.15

52W₹249

₹47980%

Open

₹461.00

High

₹464.15

Low

₹430.20

Prev Close

₹459.45

Volume

2.53L

VWAP

₹437.42

Snapshot

Key fundamentals

Market Cap

₹1,280 Cr

P/E Ratio

17.74Fair

P/B Ratio

2.55

EPS

₹24.39

Book Value

₹138.00

ROE

17.40%Strong

ROCE

20.00%Efficient

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹5.00

52W High

₹479.45

52W Low

₹248.85

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹190

▼ 56.0%downside

Trading at ₹433 — 56% above our estimate

BearFair valueBull

₹162₹190₹275

/100

Business quality — Solid

Growth 58Profitability 62Efficiency 30Valuation 81

Plain English

Our view

A steady, established business
Capital is working hard (ROCE 20%)
Fundamental red flags (Piotroski 3/9)

Strengths

Capital is working hard (ROCE 20%)
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

17% ROE fading to 13% over ~10 yrs, on ₹138 book

₹167

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹275

Analyst target

No analyst coverage

—

Blended fair value₹190

What the numbers say

Investment thesis

Bull case

Capital is working hard (ROCE 20%)
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

17.7Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

17.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

20.0%Efficient

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

₹1,280 Cr

P/B

2.55

EPS

₹24.39

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 17.7×

Growth

Steady

+15% rev CAGR

Profitability

Healthy

17.4% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %40.5%

Turnover₹1108.14L Cr

Trades7,647

VWAP₹437.42

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.6%

+6.9%

10Y

+13.0%

Profit

—

+10.2%

10Y

+42.7%

EPS

—

+9.6%

10Y

—

Profile

Cons

The company has delivered a poor sales growth of 6.94% over past five years.
Company has a low return on equity of 12.9% over last 3 years.
Working capital days have increased from 48.5 days to 95.8 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

64%

Promoter

Promoters

64.1%0.00

Public

33.3%-0.67

FII / FPI

0.0%0.00

DII

0.0%

Others

2.6%

Total shareholders

13,661

Quarterly trend

Ownership over time

Q4 FY26

Promoter64.08%

FII0.02%

Public33.32%

Others2.58%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]